Official Title
The Effect of Melatonin and Vitamin C on COVID-19
Brief Summary

This is a double-blind placebo controlled trial that seeks to evaluate the impact of melatonin and vitamin C on symptoms and outcomes of patients with COVID-19.

Completed
COVID19
SARS-CoV Infection

Dietary Supplement: Vitamin C

1000mg Vitamin C, at bedtime
Other Name: ascorbic acid

Dietary Supplement: melatonin

10mg melatonin, at bedtime

Dietary Supplement: Placebo

Placebo at bedtime

Other: Symptom Survey

Daily symptom survey to be completed by patient electronically

Eligibility Criteria

Inclusion Criteria

- COVID-19 positive test (outpatient testing),

- Age >50 (chosen based greater risk for older patients to be vitamin deficient, age >65
not used so as not to be too restrictive in the inclusion criteria)

- Experiencing symptoms for <5 days prior to enrollment

- Able to read and write in English or Spanish

- Able to access REDCap daily

- Valid email address

- Current has a Lancaster General Health primary care physician

Exclusion Criteria

- COVID-19 test ordered pre-procedure for asymptomatic screening

- Currently taking vitamin C supplements

- Currently taking melatonin supplements

- Currently hospitalized

- Deceased

- Currently pregnant

- Currently incarcerated

Eligibility Gender
All
Eligibility Age
Minimum: 50 Years ~ Maximum: N/A
Countries
United States
Locations

Lancaster General Health
Lancaster, Pennsylvania, United States

Lancaster General Hospital
NCT Number
Keywords
vitamin C
melatonin
MeSH Terms
COVID-19
Severe Acute Respiratory Syndrome
Ascorbic Acid
Melatonin